Lake Street Capital Lowers Aquestive Therapeutics (NASDAQ:AQST) Price Target to $8.00

Aquestive Therapeutics (NASDAQ:AQST) had its target price cut by analysts at Lake Street Capital from $10.00 to $8.00 in a research report issued to clients and investors on Friday,Benzinga reports. The firm currently has a “buy” rating on the stock. Lake Street Capital’s price objective would suggest a potential upside of 201.89% from the company’s previous close.

A number of other equities analysts have also recently commented on AQST. HC Wainwright reiterated a “buy” rating and issued a $10.00 target price on shares of Aquestive Therapeutics in a research report on Friday, December 20th. Cantor Fitzgerald started coverage on Aquestive Therapeutics in a research note on Tuesday, December 17th. They set an “overweight” rating and a $17.00 price objective on the stock. Seven research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus target price of $10.57.

Aquestive Therapeutics Stock Up 2.7 %

NASDAQ AQST opened at $2.65 on Friday. The stock’s 50-day simple moving average is $3.09 and its two-hundred day simple moving average is $4.10. Aquestive Therapeutics has a twelve month low of $2.24 and a twelve month high of $6.23. The company has a market capitalization of $241.62 million, a price-to-earnings ratio of -5.89 and a beta of 2.76.

Aquestive Therapeutics (NASDAQ:AQST) last announced its quarterly earnings data on Wednesday, March 5th. The company reported ($0.19) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.05). The company had revenue of $11.87 million during the quarter, compared to the consensus estimate of $13.11 million. On average, equities analysts expect that Aquestive Therapeutics will post -0.46 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Aquestive Therapeutics

A number of hedge funds have recently modified their holdings of the company. Bank of America Corp DE grew its stake in shares of Aquestive Therapeutics by 905.2% in the fourth quarter. Bank of America Corp DE now owns 690,284 shares of the company’s stock worth $2,457,000 after purchasing an additional 621,614 shares during the last quarter. State Street Corp lifted its holdings in Aquestive Therapeutics by 52.1% in the 3rd quarter. State Street Corp now owns 1,496,739 shares of the company’s stock worth $7,454,000 after buying an additional 512,682 shares during the period. Stifel Financial Corp lifted its holdings in Aquestive Therapeutics by 315.4% in the 4th quarter. Stifel Financial Corp now owns 398,561 shares of the company’s stock worth $1,419,000 after buying an additional 302,617 shares during the period. Harvey Capital Management Inc. grew its position in shares of Aquestive Therapeutics by 1,419.3% in the 4th quarter. Harvey Capital Management Inc. now owns 267,390 shares of the company’s stock worth $952,000 after buying an additional 249,790 shares during the last quarter. Finally, Verition Fund Management LLC purchased a new position in shares of Aquestive Therapeutics during the third quarter valued at approximately $995,000. Hedge funds and other institutional investors own 32.45% of the company’s stock.

Aquestive Therapeutics Company Profile

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.